User added RU58841 to their hair loss treatment and experienced quick results. Others also reported positive effects, but one user experienced chest pains as a side effect.
The user is asking if using a 10% fluridil formulation would be effective for blocking scalp androgens in addition to their current treatment of oral dutasteride.
The user is using topical finasteride, Bioscalin, Omega 3, and hair filler therapy for hair loss. There is some progress noted, but varying photo angles and lighting make it hard to assess fully.
The user experienced significant hair improvement with minoxidil and finasteride but later faced shedding and diffused thinning after developing seborrheic dermatitis. They are seeking advice after trying treatments like ketoconazole, coal tar shampoos, fluconazole, and hydrocortisone cream.
A user reported that applying castor oil to their eyebrows for two weeks resulted in thicker hair and is considering using it on their scalp to thicken existing hair, not to stop balding. They do not expect it to cure male pattern baldness.
User is experiencing hair thinning and sebum overproduction after starting finasteride and a hair growth supplement containing biotin, iron, zinc, and calcium. They suspect the finasteride might be fake but have noticed a side effect of watery semen.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
KX-826 combined with minoxidil significantly increases hair growth compared to minoxidil alone for treating male androgenetic alopecia, with no unexpected safety concerns. Users discuss various hair loss treatments, including KX-826, minoxidil, finasteride, and RU58841, sharing personal experiences and sourcing information.
Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.
The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.
Bimatoprost, latanoprost, and travoprost can aid hair regrowth but are costly and less effective than minoxidil. They work best when combined with minoxidil and finasteride.
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
The user experienced sexual side effects after starting finasteride and later switched to dutasteride, noticing hormonal changes. They are considering using P5P and possibly aromatase inhibitors to manage high prolactin and estradiol levels.
The user has tried various hair loss treatments including topical minoxidil, oral finasteride, oral dutasteride, oral minoxidil, and exosome therapy, but none have been effective. They suspect trichodynia might be preventing these treatments from working.
The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.
The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.
Reishi mushroom is significantly weaker than finasteride for inhibiting 5 alpha reductase, requiring much larger quantities to achieve similar effects. The effectiveness and safety of consuming large amounts of Reishi for hair loss are uncertain.
The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.
People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.
A 36-year-old man with androgenetic alopecia suspects copper and zinc deficiencies may be accelerating hair loss and is supplementing copper to address this. He is also monitoring blood sugar levels due to previous prediabetes concerns and plans to test for insulin resistance.
Dutasteride capsules should not be bitten or opened due to their foul taste and potential caustic effects. Users shared experiences of accidentally biting capsules and the unpleasant taste, with some suggesting swallowing techniques to avoid this.
RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.
The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.
Late 20s woman struggles with worsening hair loss and tried various treatments without success. Now trying spironolactone and ketokonazole shampoo, hoping for improvement.
A US federal judge ruled that using patients' stem cells for medical treatments is not under FDA jurisdiction, potentially speeding up development of stem cell-based hair loss therapies. Some users are optimistic about increased research and development, while others express skepticism about the ruling's impact on safety and efficacy standards.